Cencora (COR) Q3 FY25 earnings call

Cencora delivered strong Q3 FY25 results, driven by robust performance in its U.S. Healthcare Solutions segment, particularly in specialty markets and utilization trends, leading to a raise in full-year adjusted EPS and operating income guidance. While the International segment faced headwinds from subdued clinical trial activity, management anticipates sequential improvement and a return to growth by year-end. The company continues to prioritize strategic growth investments and portfolio optimization.